Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Drug Reference Index

Drug Reference Index JOURNAL OF THORACIC ONCOLOGY ALK TKIs – abstracts: 2IN, 6IN, 88IN, 89IN Gefitinib – abstracts: 6IN, 20IN, 53IN, 54IN, 69IN, 77IN, 83IN, 89IN, Actinomycin D – abstract: 289P 104P, 137O, 201O, 205O, 230P, 241P, 245P, 260P Gemcitabine – abstracts: 7IN, 46IN, 54IN, 69IN, 84IN, 134O, 194P, Amifostine – abstracts: 51IN, 191PD, 200P Amrubicin – abstract: 12IN 196P, 217PD, 220PD, 225PD, 226PD, 230P, 232P, 236P, 250P, Angiogenesis inhibitors – abstracts: 2IN, 12IN, 87IN 253P, 258P, 259P GLI inhibitors – abstract: 29IN Anti-miR agents – abstract: 55IN HDAC inhibitors – abstract: 110P, 294P Aprepitant – abstract: 49IN Hedgehog inhibitors – abstracts: 12IN, 29IN ASA404 – abstract: 83IN Hsp90 inhibitors – abstract: 110P Aurora A inhibitors – abstract: 28IN IAP inhibitors – abstract: 2IN Aurora B inhibitors – abstract: 28IN Ifosfamide – abstracts: 8IN, 197P 277P, 278P, 289P Bcl-2 inhibitors – abstract: 2IN IGF-1 inhibitors – abstract: 2IN Bevacizumab – abstracts: 7IN, 12IN, 20IN, 21IN, 69IN, 77IN, 83IN, IGF-IR inhibitor – abstracts: 2IN, 217PD 84IN, 89IN, 134O, 154O, 210O, 211O, 212O, 213O, 237P, 239P, Inhibitors of the T790M mutation – abstracts: 40IN, 52IN 246P, 247P, 255P Interferon alpha – abstract: 5IN BI 6727 – abstract: 28IN Irinotecan – abstracts: 12IN, 248P, 260P, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Drug Reference Index

Journal of Thoracic Oncology , Volume 5 – May 1, 2010

Loading next page...
 
/lp/wolters-kluwer-health/drug-reference-index-D9k5sbUuyX
ISSN
1556-0864

Abstract

JOURNAL OF THORACIC ONCOLOGY ALK TKIs – abstracts: 2IN, 6IN, 88IN, 89IN Gefitinib – abstracts: 6IN, 20IN, 53IN, 54IN, 69IN, 77IN, 83IN, 89IN, Actinomycin D – abstract: 289P 104P, 137O, 201O, 205O, 230P, 241P, 245P, 260P Gemcitabine – abstracts: 7IN, 46IN, 54IN, 69IN, 84IN, 134O, 194P, Amifostine – abstracts: 51IN, 191PD, 200P Amrubicin – abstract: 12IN 196P, 217PD, 220PD, 225PD, 226PD, 230P, 232P, 236P, 250P, Angiogenesis inhibitors – abstracts: 2IN, 12IN, 87IN 253P, 258P, 259P GLI inhibitors – abstract: 29IN Anti-miR agents – abstract: 55IN HDAC inhibitors – abstract: 110P, 294P Aprepitant – abstract: 49IN Hedgehog inhibitors – abstracts: 12IN, 29IN ASA404 – abstract: 83IN Hsp90 inhibitors – abstract: 110P Aurora A inhibitors – abstract: 28IN IAP inhibitors – abstract: 2IN Aurora B inhibitors – abstract: 28IN Ifosfamide – abstracts: 8IN, 197P 277P, 278P, 289P Bcl-2 inhibitors – abstract: 2IN IGF-1 inhibitors – abstract: 2IN Bevacizumab – abstracts: 7IN, 12IN, 20IN, 21IN, 69IN, 77IN, 83IN, IGF-IR inhibitor – abstracts: 2IN, 217PD 84IN, 89IN, 134O, 154O, 210O, 211O, 212O, 213O, 237P, 239P, Inhibitors of the T790M mutation – abstracts: 40IN, 52IN 246P, 247P, 255P Interferon alpha – abstract: 5IN BI 6727 – abstract: 28IN Irinotecan – abstracts: 12IN, 248P, 260P,

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: May 1, 2010

There are no references for this article.